Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
100 mg daily in weeks 1-2, 150 mg in weeks 3-4 and 200 mg in weeks 5-8
The guide presents subcutaneous research-vial use, whereas human clinical literature is heterogeneous and largely uses other routes. It is not a validated universal schedule.
View sourceEvidence summary
An endogenous antioxidant studied in several oral and intravenous settings. Evidence is highly route- and indication-specific and does not validate subcutaneous research vials.
Protocol basis
Rather than collapsing different formulations into one dose, this page anchors the evidence to route-specific human studies and withholds a universal protocol.
What remains uncertain
No single schedule generalises across indications, routes or compounded preparations, and subcutaneous vial evidence is especially sparse.